IsomAb
Nottingham
About IsomAb
IsomAb evaluate and develop isoform specific antibodies to treat disease.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $9.5M
- Funding stage: Seed
- Last round: Seed (Feb 2024)
- Website: isomab.bio
- Phone: [email protected]
Social Profiles
Canonical: https://fsome.com/organization/isomab-69461 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.